Key facts
- This page summarizes Garth Lees-Rolfe's Form 4 filing for Inhibikase Therapeutics, Inc. (IKT).
- 4 reported transactions and 4 derivative rows are listed below.
- Accepted by SEC: 22 Jan 2025, 16:05.
Garth Lees-Rolfe - 21 Jan 2025 Form 4 Insider Report for Inhibikase Therapeutics, Inc. (IKT)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- IKT
- Reported as of
- 21 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 22 Jan 2025, 16:05:10 UTC
- Prior SEC filing
- 07 Jan 2025
- Next SEC filing
- 26 Jun 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Garth Lees-Rolfe
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Garth Lees-Rolfe filed Form 4 for Inhibikase Therapeutics, Inc. (IKT) on 22 Jan 2025.
Change
- Previous filing in this sequence was filed on 07 Jan 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
IKT
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -5,834
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,834
- Exercise price
- $3.79
- Footnotes
- F1, F2
IKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +5,834
- Change %
- Price
- $0.000000
- Shares after
- 5,834
- Date
- 21 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 5,834
- Exercise price
- $1.26
- Footnotes
- F1, F2
IKT
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -90,000
- Change %
- -100%
- Price
- $0.000000
- Shares after
- 0
- Date
- 21 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,000
- Exercise price
- $2.16
- Footnotes
- F1, F2
IKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +90,000
- Change %
- Price
- $0.000000
- Shares after
- 90,000
- Date
- 21 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 90,000
- Exercise price
- $1.26
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The transactions reported herein reflect an option repricing (the "Repricing") effective on January 21, 2025. The Repricing was approved by the Issuer's Board of Directors on October 9, 2024 and the Issuer's stockholders on January 3, 2025. All of the other terms of the options remain unchanged. Such transactions were exempt pursuant to Rule 16b-6(d) and Rule 16b-3 of the Exchange Act, as applicable.
Footnote F2
This stock option award was issued pursuant to the Inhibikase Therapeutics, Inc. 2011 Equity Incentive Plan or the Inhibikase Therapeutics, Inc. 2020 Equity Incentive Plan, as applicable, and becomes exercisable in accordance with the vesting schedule specified in the award agreement and as previously reported on applicable Form 4, subject to the Reporting Person's continued service with the Issuer as of the applicable vesting date.